The cost of improving drug safety in Europe
This article was originally published in Scrip
The need to ensure that medicines have a positive benefit-risk profile, both before marketing approval and throughout their lifecycle, has become an accepted tenet of pharmaceutical development and regulation. It is in no one's interest to have drugs on the market that do more harm than good.
You may also be interested in...
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.